Your browser doesn't support javascript.
loading
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
Guida, Michele; Bartolomeo, Nicola; Quaresmini, Davide; Quaglino, Pietro; Madonna, Gabriele; Pigozzo, Jacopo; Di Giacomo, Anna Maria; Minisini, Alessandro Marco; Tucci, Marco; Spagnolo, Francesco; Occelli, Marcella; Ridolfi, Laura; Queirolo, Paola; De Risi, Ivana; Valente, Monica; Sciacovelli, Angela Monica; Chiarion Sileni, Vanna; Ascierto, Paolo Antonio; Stigliano, Lucia; Strippoli, Sabino.
  • Guida M; Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Viale O. Flacco, 6570124, Bari, Italy. m.guida@oncologico.bari.it.
  • Bartolomeo N; Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy.
  • Quaresmini D; Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Viale O. Flacco, 6570124, Bari, Italy.
  • Quaglino P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Madonna G; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.
  • Pigozzo J; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Di Giacomo AM; Center for Immuno-Oncology, University Hospital of Siena, University of Siena, Siena, Italy.
  • Minisini AM; Department of Oncology, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy.
  • Tucci M; Medical Oncology Unit, University of Bari Aldo Moro, Bari, Italy.
  • Spagnolo F; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Occelli M; Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Ridolfi L; Oncology Unit, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy.
  • Queirolo P; Immunotherapy, Cell Therapy and Biobank Unit, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • De Risi I; Division of Melanoma Sarcoma and Rare Tumors, IEO European Institute of Oncology IRCCS Milan, Milan, Italy.
  • Valente M; Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Viale O. Flacco, 6570124, Bari, Italy.
  • Sciacovelli AM; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
  • Chiarion Sileni V; Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Ascierto PA; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Stigliano L; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.
  • Strippoli S; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
J Transl Med ; 20(1): 159, 2022 04 05.
Article en En | MEDLINE | ID: mdl-35382857
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Melanoma / Neutrófilos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Melanoma / Neutrófilos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article